Baidu
map

国内外主流“专利指数”探析

2015-09-28 凌赵华 超凡知识产权

当今社会,知识已成为生产要素中重要的组成部分,以此为标志的知识经济已然成为21世纪的主导型经济形态。在知识经济时代,知识、智力、无形资产等的投入将越来越会在企业的发展过程中起决定性作用。有数据表明,在企业尤其是技术驱动型企业中,无形资产在企业价值中的占比越来越大,不少企业已经占到80%以上。以专利和商标为代表的知识产权是现代企业中无形资产的重要组成部分,其中,专利体现了企业的硬实力(技术),而

当今社会,知识已成为生产要素中重要的组成部分,以此为标志的知识经济已然成为21世纪的主导型经济形态。在知识经济时代,知识、智力、无形资产等的投入将越来越会在企业的发展过程中起决定性作用。有数据表明,在企业尤其是技术驱动型企业中,无形资产在企业价值中的占比越来越大,不少企业已经占到80%以上。以专利和商标为代表的知识产权是现代企业中无形资产的重要组成部分,其中,专利体现了企业的硬实力(技术),而商标则体现了企业的软实力(品牌)。

如何从专利角度来建立一套统一的评价指标,用于分析和展示企业的技术实力、创新能力以及成长潜力,是不少机构一直在努力的方向。专利指数或专利记分卡是一种很好的尝试,其可以较为客观、公正地展示出企业整体的专利实力,反映出企业的技术与创新能力,从而映射出企业的核心竞争力。本文选取了当前国内外主流的五个专利指数或专利记分卡,探析了各“专利指数”的指标设计和功能特色,并提出了笔者个人的一些粗浅看法。

国外方面,本文选取的是美国Ocean Tomo公司发布的OT300专利指数(Ocean Tomo 300 Patent Index)、美国电子和电气工程师协会(IEEE)旗下《IEEE SPECTRUM》杂志发布的专利实力记分卡(Patent Power Scorecard)以及美国IPIQ Global公司发布的专利记分卡(Patent Scorecard)等三个“专利指数”;国内方面,本文选取的是德高行(北京)科技有限公司发布的国证德高行专利领先指数(CNI-TEKGLORY Patent Index)和中国专利技术开发公司发布的创业板专利记分牌(ChiNext Patent Scorecard)等两个“专利指数”。

一、OT 300专利指数

OT300专利指数由美国Ocean Tomo公司和美国证券交易所于2006年9月联合发布,这一指数是全球第一个基于公司知识产权资产价值的股票指数,目前这一指数主要在纽约泛欧证券交易所发布(NYSE Euronext: OTPAT)。除了OT300专利指数,Ocean Tomo公司同时还在纽约泛欧证券交易所发布OT300专利成长指数(NYSE Euronext: OTPATG)和OT300专利价值指数(NYSE Euronext: OTPATV)。OT300专利指数通过回归分析法建立创新率(创新率=专利维持价值/企业资产)评估模型,从1000多家流通性最好的美国上市公司中分析筛选出创新率最高的300家公司(50个行业*6家公司)。OT300专利指数的主要价值就在于在市场对专利技术予以认可之前对公司技术创新的价值进行预测。

Ocean Tomo公司是美国较早开展专利价值评估研究的公司,其自行开发了一套叫做Patent Ratings的专利价值分析系统,这一系统号称是世界上第一个能客观、准确分析专利价值的软件系统平台。OT300专利指数正是利用Patent Ratings这个工具来分析大量公司的授权专利的,从而保障了对不同公司不同专利技术评价的客观、一致性。

在指标设计上,OT300专利指数是目前市场上最为全面,其既有有效专利数量、专利平均维持年限、专利放弃比例等一些基本指标,也有专利单向引证率、专利积累引证率等一些能反映专利质量的指标,还有专利衰退率等能反映专利市场价值的指标,有效专利季度净收入变化、替代旧专利所需新专利数量等一些能反映公司财务发展状况的指标,以及一些能反映公司技术分布情况的指标等等。

综上所述,OT300专利指数是全球第一个较为成熟的专利指数,也是第一个基于专利价值分析的股票指数,其创造性地将上市公司的专利价值与股票价格结合了起来,为其在“专利指数”的研究领域奠定了领先地位。

二、专利实力记分卡

专利实力记分卡由《IEEE SPECTRUM》杂志自2007年开始每年发布一次,到2014年11月19日共发布了8期榜单。专利实力记分卡的评选对象是全世界范围内的公司、大学、研究机构和政府机构等组织。专利实力记分卡是完全按照组织所在的行业来进行分类评比的,其每次发布17个榜单:航空航天和国防、汽车及零部件、生物医药、化学、通信\网络设备、通信\网络服务、计算机设备和存储、计算机软件、计算机系统、电子产品、医疗器械、科学仪器、半导体设备制造、半导体制造、综合型企业、政府机构、大学/教育/培训。

专利实力记分卡各榜单上的组织是根据专利综合实力进行排名的,其综合考量了专利组合的数量和技术价值,由于采用了技术加权后的专利组合规模作为衡量依据,专利实力记分卡可以较全面准确地评价某个组织的技术实力。

专利综合实力是对专利数量及专利成长性、技术影响力、技术原创性和技术通用性进行组合运算后的综合性指数,其计算公式为:专利综合实力(Pipeline Power)=上一年度授权专利数量(Number of Last Year’s Patents)×专利增长指数(Pipeline Growth Index)×校正后的技术影响指数(Adjusted Pipeline Impact)×技术原创指数(Pipeline Originality)×技术通用指数(Pipeline Generality)。

以2014 年专利综合实力的计算为例,公式中各参数的含义为:上一年度授权专利数量,指的是2013年美国专利授权数量。专利增长指数,用于衡量某组织专利活动量的变化趋势,进而反映某组织的创新能力。其计算方法为:某组织上一年度美国专利授权量(2013年)除以前五年期间(2008-2012年)每年平均授权量。如果该指数大于1,则表明该组织的专利活动量正在增长中。校正后的技术影响指数,用于衡量某组织的专利组合对后续技术发展的影响力。其计算方法为:首先计算技术影响指数基础值,再根据自引率对技术影响指数基础值进行校正,以消除极端自引的影响。其中,技术影响指数基础值的计算方法为:某组织前五年(2008-2012年)所有美国授权专利被上一年(2013年)全美所有授权专利引用的次数,除以与该组织专利组合处于同时期、 同领域的所有美国授权专利被上一年全美所有授权专利引用次数的平均值。技术原创指数,用于衡量某组织专利组合所引用的在先技术的领域宽泛程度。通常来说,改进型发明倾向于参考来自单一领域的现有技术,而原创型发明则倾向于参考多个不同领域的在先技术进而形成新的发明创造。技术通用指数,用于衡量引用某组织专利组合的专利技术的领域宽泛程度。技术通用指数越大,意味着某组织专利技术的通用性越好,对后续技术创新的影响范围越大。

可以看到,与OT300专利指数的指标设计不同,专利实力记分卡更注重对公司技术实力的评价,因而在指标设计上更偏重专利的技术价值体现,却忽略了专利的市场价值体现和公司的财务表现等指标的设计。另外,专利实力记分卡中的技术类指标在打分上会存在一定程度的主观性,并不完全是客观数据的展现。

三、专利记分卡

专利记分卡由IPIQ Global公司自1992年开始对外发布,曾先后刊登在《商业周刊》(Business Week)、《麻省理工技术评论》(MIT Technology Review)以及《华尔街日报》(The Wall Street Journal)上。专利记分卡实际上共发布了7个榜单,分别为:行业记分卡(Industry Scorecard)、全球专利记分卡(Global Patent Scorecard)、IPIQ 500记分卡(IPIQ 500 Scorecard)、大学记分卡(University Scorecard)、政府机构记分卡(Government Scorecard)、研究机构记分卡(Research Institution Scorecard)和创新机构记分卡(Innovation Anchor Scorecard)。

行业记分卡是IPIQ Global公司发布的最核心的专利记分卡产品。行业记分卡共选取17个行业进行评价分析,主要评价对象为全球顶尖的2700多家技术型企业。针对每个行业,行业记分卡都是基于专利质量、技术强度以及影响广度等指标来对公司进行排名。该行业记分卡每月更新一次。行业记分卡中设计的具体指标有技术强度(Technology Strength)、行业影响力(Industry Impact)、授权专利数量(Patents Granted)、科学强度(Science Strength)以及研究强度(Research Intensity)等5个。其中,技术强度用于从公司专利组合的角度,通过综合考量专利的质量和数量,对公司的专利和创新进行一个总体评价;行业影响力用于对一个公司的专利组合对行业内其他公司的技术发展的影响力进行量化评价;科学强度用于从总体上去衡量一个公司的专利组合与核心科学的关联度;研究强度用于评价一个公司在特定行业中相比于其他公司在基础研究上的水平。

全球专利记分卡通过分析全球59个国家自1980年以来的授权专利来综合评价这些国家的技术能力。在数据分析过程中,全球专利记分卡使用了三种专利分类体系,分别为美国标准工业分类体系(SIC)、国际专利分类体系(IPC)以及IPIQ Global公司自己的分类体系。全球专利记分卡中的具体指标包括在特定技术领域的强度、本国专利对其他国家的影响力、国家创新与科学研究的关联度以及创新的速度等4个。

IPIQ 500记分卡基于一个标准化的技术强度指数对全球的技术型公司进行比较并排名,最终给出一个500强的名单。由于对排名指数进行了标准化处理,IPIQ 500记分卡实现了公司之间的跨行业比较,从而能够在不考虑所属行业的情况下识别出全球范围内的高创新公司。IPIQ 500记分卡采用的具体指标有技术强度、行业影响力、授权专利数量、科学强度、研究强度以及创新周期(Innovation Cycle Time)等6个,其中前5个指标与行业记分卡的指标相同,其第6个指标创新周期用于评价一个公司将其前沿技术和核心研究转化为专利资产的速度,一般以年计算。

大学记分卡是专门针对全球超过140所大学进行排名的榜单,与行业记分卡一样,该大学记分卡也是每月更新一次。另外,大学记分卡也是基于专利质量、技术强度以及影响广度等指标来进行评价的,基本与行业记分卡相同。政府机构记分卡和研究机构记分卡均与大学记分卡类似,不同之处仅在评价对象上。而创新机构记分卡则是打破了评价对象的限制,融合了大学、政府机构和研究机构,其评价指标和更新周期均与大学记分卡一样。

可以看到,专利记分卡在评价对象上做得比较细致,既有机构类型的区分,又有行业的区分,还有不区分对象的综合榜单。在指标设置上,专利记分卡与专利实力记分卡在总体上有些相似,都重点考量了专利的数量及其技术价值,值得注意的是,专利记分卡相较于专利实力记分卡更注重一个公司的基础研究和科学实力,上述实力与专利之间的关联度,以及创新转化为专利的速度。

四、国证德高行专利领先指数

国证德高行专利领先指数(代码:399427)由深圳证券信息有限公司与德高行(北京)科技有限公司于2015年2月17日在深圳证券交易所正式发布。该指数既是一个专利指数,更是一个股票指数。该指数的评估对象是中国大陆A股市场上2700多家上市公司,并最终筛选出100家投资潜力最佳的公司作为样本股。

国证德高行专利领先指数的核心基础是通过专利大数据的指标萃取、加工及演算,构建出以专利指标预测股价的股价预测公式,即专利领先公式。专利领先公式由德高行公司自行开发,其演算法核心采用2003年诺贝尔奖的经济学模型,通过严格的统计检定,并达到95%的置信区间。

在上述专利领先公式中,共设计了两类指标:专利指标和财务指标。其中,专利指标有将近50个,这些专利指标都是可以被计算机自动运算的数量指标,如专利总数、平均专利寿命、专利平均审查期、当期的专利公开数量、专利授权数量、专利IPC分类号总数、专利IPC分类号平均数、专利说明书总页数、专利说明书平均页数、专利的权利要求总数、专利的权利要求平均数、专利的独权总数、专利的独权平均数、专利说明书的附图张数、专利说明书的附图平均数等等。财务指标是指能表达企业经营绩效的指标,包括偿债能力指标、运营能力指标、获利能力指标、发展能力指标以及股价指标等。其中,获利能力指标又包括了净资产收益率ROE、资产报酬率ROA、每股收益EPS以及市净率MTB等。

可以看到,与OT300专利指数类似,国证德高行专利领先指数选取的均是可量化指标,且包含了专利指标和财务指标两类,因此,在指标设计上保证了数据的客观性,另外在演算法的采用上也保持了严谨的态度。目前,国证德高行专利领先指数设计的专利指标的数量还在增加中,其专利领先公式也在不断优化中,相信未来其在证券市场上会有更出色的表现。

五、创业板专利记分牌

创业板专利记分牌由中国专利技术开发公司于2015年7月16日在中国专利网首次发布。创业板专利记分牌主要利用专利质量指标和市场价值验证指标定期统计并发布创业板上市公司的专利统计数据,同时发布各类专利态势统记分析报告,从专利角度解读创业板上市公司的创新产出质量和效益。创业板专利记分牌的统计对象为截止到2014年12月3日在创业板上市的405家公司。

创业板专利记分牌共发布1个总榜单(不分行业)和13个行业榜单,该13个行业分别为:制造业、农林牧渔、水电煤气、批发零售、商务服务、采矿业、信息技术、建筑业、运输仓储、科研服务、公共环保、文化传播、卫生。

在指标设计上,创业板专利记分牌采用了两类指标,分别是市场验证前的指标和市场验证后的指标。市场验证前的指标包括有效发明专利拥有量、有效发明专利维持年限分布、在中国主要贸易对象国/地区的专利布局、技术影响等四项。其中,在中国主要贸易对象国/地区的专利布局指标又包括四方(中/美/欧/日)专利数量和具有美/日/欧同族的中国发明专利数量等几项。技术影响指标主要基于专利被引用数据计算获得,具体包括发明专利被引次数、发明专利平均被引次数、近3年发明专利被引次数、发明专利h指数等四项指标。市场验证后的指标包括经无效程序后仍维持有效的专利数量、公司是否对外发起专利诉讼、公司专利是否对外许可、公司专利质押数量等四项。

综上可知,创业板专利记分牌并未如前述几个“专利指数”一样最终给出一个综合指数,而是尽量客观地展示其各项子指标的数值。另外,在指标设计上其既考虑了专利数量也考虑了专利质量,并创造性地加入了专利许可、无效、诉讼、质押等市场验证类指标。创业板专利记分牌的一个缺憾是没有将专利数据与财务数据有机地融合起来。

整体而言,国内对“专利指数”方面的研究和实践起步较国外晚了许多,目前正处于方兴未艾的状态,希望国内的同行们能借着国家这股“大众创业、万众创新”的东风奋起直追,早日赶超国外同行们。


如果临床医生要申请专利,可以与MedSci联系。据悉,MedSci是一家专业的面向医学领域的专业申请机构,有丰富的经验。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=71581, encodeId=393de158161, content=我们课题组会对一些专利质量情况进行分析,往往发现中国数量虽多,质量却差, beContent=null, objectType=article, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccc11622300, createdName=yangcristina, createdTime=Fri Mar 18 23:51:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56135, encodeId=21e456135bd, content=了解了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56136, encodeId=42355613677, content=了解了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56137, encodeId=c87a5613e01, content=继续加油!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56138, encodeId=9f6856138ef, content=继续加油!, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56139, encodeId=1b785613921, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56140, encodeId=958556140fd, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56133, encodeId=c7eb56133ac, content=哦,, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:47:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56134, encodeId=ae3956134b2, content=哦,, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:47:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-03-18 yangcristina

    我们课题组会对一些专利质量情况进行分析,往往发现中国数量虽多,质量却差

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=71581, encodeId=393de158161, content=我们课题组会对一些专利质量情况进行分析,往往发现中国数量虽多,质量却差, beContent=null, objectType=article, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccc11622300, createdName=yangcristina, createdTime=Fri Mar 18 23:51:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56135, encodeId=21e456135bd, content=了解了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56136, encodeId=42355613677, content=了解了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56137, encodeId=c87a5613e01, content=继续加油!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56138, encodeId=9f6856138ef, content=继续加油!, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56139, encodeId=1b785613921, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56140, encodeId=958556140fd, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56133, encodeId=c7eb56133ac, content=哦,, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:47:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56134, encodeId=ae3956134b2, content=哦,, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:47:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 medsic

    了解了,

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=71581, encodeId=393de158161, content=我们课题组会对一些专利质量情况进行分析,往往发现中国数量虽多,质量却差, beContent=null, objectType=article, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccc11622300, createdName=yangcristina, createdTime=Fri Mar 18 23:51:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56135, encodeId=21e456135bd, content=了解了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56136, encodeId=42355613677, content=了解了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56137, encodeId=c87a5613e01, content=继续加油!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56138, encodeId=9f6856138ef, content=继续加油!, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56139, encodeId=1b785613921, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56140, encodeId=958556140fd, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56133, encodeId=c7eb56133ac, content=哦,, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:47:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56134, encodeId=ae3956134b2, content=哦,, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:47:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 medsic

    了解了,

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=71581, encodeId=393de158161, content=我们课题组会对一些专利质量情况进行分析,往往发现中国数量虽多,质量却差, beContent=null, objectType=article, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccc11622300, createdName=yangcristina, createdTime=Fri Mar 18 23:51:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56135, encodeId=21e456135bd, content=了解了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56136, encodeId=42355613677, content=了解了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56137, encodeId=c87a5613e01, content=继续加油!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56138, encodeId=9f6856138ef, content=继续加油!, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56139, encodeId=1b785613921, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56140, encodeId=958556140fd, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56133, encodeId=c7eb56133ac, content=哦,, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:47:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56134, encodeId=ae3956134b2, content=哦,, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:47:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 medsic

    继续加油!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=71581, encodeId=393de158161, content=我们课题组会对一些专利质量情况进行分析,往往发现中国数量虽多,质量却差, beContent=null, objectType=article, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccc11622300, createdName=yangcristina, createdTime=Fri Mar 18 23:51:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56135, encodeId=21e456135bd, content=了解了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56136, encodeId=42355613677, content=了解了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56137, encodeId=c87a5613e01, content=继续加油!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56138, encodeId=9f6856138ef, content=继续加油!, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56139, encodeId=1b785613921, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56140, encodeId=958556140fd, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56133, encodeId=c7eb56133ac, content=哦,, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:47:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56134, encodeId=ae3956134b2, content=哦,, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:47:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 medsic

    继续加油!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=71581, encodeId=393de158161, content=我们课题组会对一些专利质量情况进行分析,往往发现中国数量虽多,质量却差, beContent=null, objectType=article, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccc11622300, createdName=yangcristina, createdTime=Fri Mar 18 23:51:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56135, encodeId=21e456135bd, content=了解了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56136, encodeId=42355613677, content=了解了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56137, encodeId=c87a5613e01, content=继续加油!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56138, encodeId=9f6856138ef, content=继续加油!, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56139, encodeId=1b785613921, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56140, encodeId=958556140fd, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56133, encodeId=c7eb56133ac, content=哦,, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:47:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56134, encodeId=ae3956134b2, content=哦,, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:47:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 medsic

    感谢分享~~

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=71581, encodeId=393de158161, content=我们课题组会对一些专利质量情况进行分析,往往发现中国数量虽多,质量却差, beContent=null, objectType=article, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccc11622300, createdName=yangcristina, createdTime=Fri Mar 18 23:51:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56135, encodeId=21e456135bd, content=了解了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56136, encodeId=42355613677, content=了解了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56137, encodeId=c87a5613e01, content=继续加油!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56138, encodeId=9f6856138ef, content=继续加油!, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56139, encodeId=1b785613921, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56140, encodeId=958556140fd, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56133, encodeId=c7eb56133ac, content=哦,, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:47:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56134, encodeId=ae3956134b2, content=哦,, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:47:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 medsic

    感谢分享~~

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=71581, encodeId=393de158161, content=我们课题组会对一些专利质量情况进行分析,往往发现中国数量虽多,质量却差, beContent=null, objectType=article, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccc11622300, createdName=yangcristina, createdTime=Fri Mar 18 23:51:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56135, encodeId=21e456135bd, content=了解了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56136, encodeId=42355613677, content=了解了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56137, encodeId=c87a5613e01, content=继续加油!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56138, encodeId=9f6856138ef, content=继续加油!, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56139, encodeId=1b785613921, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56140, encodeId=958556140fd, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56133, encodeId=c7eb56133ac, content=哦,, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:47:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56134, encodeId=ae3956134b2, content=哦,, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:47:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 medsic

    哦,

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=71581, encodeId=393de158161, content=我们课题组会对一些专利质量情况进行分析,往往发现中国数量虽多,质量却差, beContent=null, objectType=article, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccc11622300, createdName=yangcristina, createdTime=Fri Mar 18 23:51:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56135, encodeId=21e456135bd, content=了解了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56136, encodeId=42355613677, content=了解了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56137, encodeId=c87a5613e01, content=继续加油!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56138, encodeId=9f6856138ef, content=继续加油!, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56139, encodeId=1b785613921, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56140, encodeId=958556140fd, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:48:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56133, encodeId=c7eb56133ac, content=哦,, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:47:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56134, encodeId=ae3956134b2, content=哦,, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 09:47:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 medsic

    哦,

    0

相关资讯

2014年度专利复审无效十大案件

编者按:4月27日,在国家知识产权局开放日活动中,国家知识产权局专利复审委员会(下称专利复审委)经精心组织、认真评选,发布了2014年度专利复审无效十大案件,其中包括发明、实用新型、外观设计专利权无效宣告请求案以及发明专利申请复审请求案。这些案件或社会关注度高,或对相关行业产业有重大影响,或涉及重大疑难法律问题和重要审查标准。 专利复审委此次评选产生的十大案件,覆盖了机械、电学、通信、医

不丧失专利新颖性的宽限期

一、建议,尽量避免使用不丧失新颖性的宽限期虽然专利法规定了不丧失专利新颖性的宽限期,但小编认为尽量不使用它,原因是:首先对符合规定的展览或会议要求较高,而且必须能出具证明才有效,同时此种公开对自己和他人的技术都会有影响,即公开日并非专利申请日,因此,建议,最好在展出或发表自己的技术之前,先申请专利,获得申请日和申请号之后,再参加展出或会议发表等,这样才能有效保证自己技术的新颖性。如果出于其他原因产

青蒿素,为何一错再错?

2011年9月,中国女药学家屠呦呦因创制新型抗疟药——青蒿素和双氢青蒿素的贡献,获得被誉为诺贝尔奖“风向标”的拉斯克奖。可以说是中国生物医学界离诺贝尔奖最近的一次。但是,这个成功的技术背后,却是一错再错的专利故事。分析这个案例,是为了以史为鉴,在以后的工作中吸取教训,不再犯同样的错误。  丧失原始专利申请权 青蒿素的研发接近成果期的时候,我国的研究人员在国内外发表了一系列文章。197

宏观了解专利过程

引言:建议委托代理人完成专利申请工作;原因体现在:专利申请文件的撰写以及答复审查意见的形式较为专业;另外,专利申请提交方式、专利费用的缴纳以及各类程序的时间规定等方面较为繁琐。如下从专利申请—专利审查—专利授权—专利权维护—专利权终止等方面进行概述。一、专利申请前的准备工作申请人将自己的技术方案,以技术交底书的方式呈现给代理人,并提供相关基础信息,签订委托书和代理合同等文件;申请人支付代理服务费和

了解专利的官方审查流程

(一)发明专利的官方审查包括五阶段:受理阶段、初审阶段、公布阶段、实审阶段、授权阶段;1、发明专利的受理阶段时间:大约1个月左右;申请人获得专利受理通知书;如果通过电子提交方式申请专利,一般提交日的第二天即可获得申请日和申请号。流程:申请人提出专利申请 → 专利局受理(获得申请日和申请号) → 专利局下发专利受理通知书 → 申请人缴纳申请费(申请日起2个月内

Baidu
map
Baidu
map
Baidu
map